Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indices end Diwali week 2% lower
Fri, 16 Nov Closing

The Indian stock markets started the day on a positive note. The indices traded above par for a good portion of today's trading session. However, towards the end of trade today, the indices saw a slump. In the final hour of trade the indices moved firmly into the red. The BSE-Sensex closed negative, lower by around 162 points (down 0.9%). The NSE-Nifty also closed lower by around 57 points (down 1%). The smaller indices also had a bad day on the bourses. The BSE Mid Cap index closed 0.9% lower and the BSE Small Cap closed 1.1% lower in trade today. Realty and banking stocks saw a bulk of the losses today. Software stocks however saw some gains.

As regards global markets, Asian indices had a mixed outing today. European indices opened the day weak. The rupee was trading at Rs 55.13 to the dollar at the time of writing.

WPI inflation for the month of October 2012 eased marginally to 7.45% from 7.81% in the previous month. However, stickiness is still evident since the inflation continues to register above the 7% mark. It has continued to do so for the last eleven months. However it has eased off from the 9.87% levels seen last October. However inflation may spike will December 2012 due to higher food prices, commodity prices and fuel price hikes. If inflation continues on its downward trajectory we may even see some good news in terms of rate cuts from the RBI.

Dr Reddy's Laboratories (DRL) and the Netherlands-based OctoPlus, a speciality pharmaceutical company, have entered into a conditional agreement in connection with an intended public offer by DRL or a wholly owned subsidiary of DRL for all issued and outstanding ordinary shares in the capital of OctoPlus. This is at an offer price of EUR 0.52 (cum dividend) in cash for each OctoPlus share. It is expected that the offer will be launched mid December 2012. If launched, the offer period will run for at least eight weeks and no more than ten weeks. Closing of transaction is expected to occur in first quarter of 2013, the company stated. Last month, Dr Reddy's announced that it would acquire OctoPlus for about EUR 27.4 million (about Rs 1.9 bn).

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indices end Diwali week 2% lower". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.